miRNA signature associated with outcome of gastric cancer patients following chemotherapy

BMC Medical Genomics

Table 4 Prediction for chemoresistance in the proof-of-principle test set

*Sample ID*	*Feature selection P < 0.05*			*Feature selection P < 0.01*
	Predictive Index Percentile¹	Prediction For Pretreatment Sample²	Overall Prediction³	Predictive Index Percentile	Prediction for Pretreatment Sample	Overall Prediction
1 pre	39%	low	incorrect	35%	low	incorrect
1 post	22%			24%
2 pre	48%	low	correct	49%	low	correct
2 post	79%			77%
3 pre	55%	low	correct	46%	low	correct
3 post	73%			77%
4 pre	13%	low	correct	24%	low	correct
4 post	72%			73%
5 pre	31%	low	correct	33%	low	correct
5 post	48%			46%
6 pre	13%	low	correct	27%	low	correct
6 post	16%			66%
7 pre	7%	low	correct	12%	low	correct
7 post	66%			57%
8 pre	52%	low	incorrect	50%	low	incorrect
8 post	17%			24%

¹The predictive index was computed for each sample by this supervised principal component method, where a high value of the predictive index corresponds to a rapid progression after chemotherapy (i.e., short TTP). If the predictive index of a sample in the test set corresponded to the median predictive index of the training set, the sample was assigned a 50% predictive index.
²The risk was predicted low, if predictive index percentile of the pretreatment sample was less than 67%
³The prediction was considered correct if post-treatment samples were assigned a higher predictive index than pre-treatment samples.

ISSN: 1755-8794